We are monitoring the impact of COVID-19 on Europe Neisseriaceae Infections Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 4349
Share on
Share on

Europe Neisseriaceae Infections Market Research Report – Segmented By Type Of Bacteria, Disease, Antibacterial Drugs and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends And Forecasts (2020 to 2025)

Pulished: February, 2020
ID: 4349
Pages: 136

Europe Neisseriaceae Infections Market Size (2020 to 2025)

The size of the Neisseriaceae Infections market in Europe is projected to grow at a robust CAGR from 2020 to 2025.

Bacteria represent the essential class of micro-organisms that play a crucial role in the development of infection of any disease to human being and animal. They are classified into two types on the basis of gram staining test, viz., gram-positive bacteria and gram-negative bacteria. Neisseria is one of the most important class of bacteria which forms colonies on mucosal surfaces of animals. Neisseria comprises 11 species, out of which, two are pathogenic and others are harmless. These belong to gram negative class of bacteria, because these species show negative response to gram test.

As per the U.S. Centers for Disease Control and Prevention (CDC), more than 300,000 new cases of gonorrhea were reported in the U.S. in 2012, an enhancement of around 4% in contrast to 2011. Therefore, such rising prevalence of infections is an important growth driver of the market. Further, due to extensive R&D practices, number of drugs and formulations are on the way to enter in the market during the forecast period. Some of the important pipeline products include AXD0914, Cribrostatin-6, SM-295291 and SM-369926 amongst numerous others. In addition, owing to rising incidences of homosexuality and bisexuality, the threat of gonorrhea has also increased. These factors are aided by rising awareness regarding the infections and diseases and rising medical expenditure. Due to these, the market is anticipated to grow at steady rate.

On the other hand, factors such as government austerity, high cost of treatment and R&D, and ignorance towards the symptoms may hamper the growth of the market to certain extent.

This research report on the Europe Neisseriaceae Infections market has been segmented and sub-segmented into the following categories:

By Type of Bacteria:

  • N. Meningitidis     
  • N. Gonorrhoeae  
  • N. Sicca    
  • N. Flava   
  • N. Elongata            
  • N. Cinerea              
  • Others     

By Disease:

  • Gonorrhea              
  • Septicemia              
  • Meningitis               
  • Sinusitis    
  • Otitis          
  • Pneumonia             
  • CNS            
  • Urinary     
  • Respiratory Infections

By Antibacterial Drugs:

  • Aminoglycosides (Streptomycin)
  • B-Lactum Antibiotics (Penicillin)
  • Clavulanic Acid (Augmentin)
  • Glycopeptides (Vancomycin)
  • Polypeptides (Bacitracin)
  • Rifamycins (Rifampicin)
  • Chloramphenicol
  • Tetracycline

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Rest of Europe

Regionally, at present, Europe is the second most prominent market, owing to growing prevalence of various Neisseriaceae infections and associated disease.

Key market players leading the European Neisseriaceae Infections market leaders are Aphios Corporation, Basilea Pharmaceuticals Ltd., Pfizer, Inc., GSK plc, AstraZeneca plc, Adenium Biotech ApS, Dainippon Sumitomo Pharma Co., Ltd., Theravance, Inc., and Pfizer, Inc. amongst many others.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. OVERVIEW
    1. Executive Summary
    2. Key Inferences
  4. DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. MARKET SEGMENTATION
    1. Type Of Bacteria
      1. Introduction
      2. N. Meningitidis
      3. N. Gonorrhoeae
      4. N. Sicca
      5. N. Flava
      6. N. Elongata
      7. N. Cinerea
      8. Others
      9. Y-o-Y Growth Analysis, By Type Of Bacteria
      10. Market Attractiveness Analysis, By Type Of Bacteria
      11. Market Share Analysis, By Type Of Bacteria
    2. Disease
      1. Introduction
      2. Gonorrhea
      3. Septicemia
      4. Meningitis
      5. Sinusitis
      6. Otitis
      7. Pneumonia
      8. CNS
      9. Urinary
      10. Respiratory Infections
      11. Y-o-Y Growth Analysis, By Disease
      12. Market Attractiveness Analysis, By Disease
      13. Market Share Analysis, By Disease
    3. Antibacterial Drugs
      1. Introduction
      2. B-lactum Antibiotics (Penicillin)
      3. Clavulanic Acid (Augmentin)
      4. Aminoglycosides (Streptomycin)
      5. Glycopeptides (Vancomycin)
      6. Polypeptides (Bacitracin)
      7. Rifamycins (Rifampicin)
      8. Chloramphenicol
      9. Tetracycline
      10. Others
      11. Y-o-Y Growth Analysis, By Antibacterial Drugs
      12. Market Attractiveness Analysis, By Antibacterial Drugs
      13. Market Share Analysis, By Antibacterial Drugs
  6. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Europe
      1. Introduction
      2. United Kingdom
      3. France
      4. Spain
      5. Germany
      6. Italy
      7. Russia
      8. Sweden
      9. Denmark
      10. Switzerland
      11. Netherlands
      12. Rest of Europe
  7. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. MARKET LEADERS' ANALYSIS
    1. Basilea Pharmaceuticals Ltd.
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. AstraZeneca plc
    3. Adenium Biotech ApS
    4. Dainippon Sumitomo Pharma Co. Ltd.
    5.  Aphios Corporation
    6. Pfizer Inc.
    7.  GSK plc
    8. Theravance Inc.
  9. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, collaborations and Joint Ventures
    4. New Product Launches
  10. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  11. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of type, Disease, Antibacterial Drugs along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the Europe Market; which includes broadly demographic, economic and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Neisseriaceae Infections Market, By Type Of Bacteria, From 2020 to 2025 (USD Million)
  2. Europe N. Meningitidis Market, By Region, From 2020 to 2025 (USD Million)
  3. Europe N. Gonorrhoeae Market, By Region, From 2020 to 2025 (USD Million)
  4. Europe N. Sicca Market, By Region, From 2020 to 2025 (USD Million)
  5. Europe N. Flava Market, By Region, From 2020 to 2025 (USD Million)
  6. Europe N. Elongata Market, By Region, From 2020 to 2025 (USD Million)
  7. Europe N. Cinerea Market, By Region, From 2020 to 2025 (USD Million)
  8. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  9. Europe Neisseriaceae Infections Market, By Disease, From 2020 to 2025 (USD Million)
  10. Europe Gonorrhea Market, By Region, From 2020 to 2025 (USD Million)
  11. Europe Septicemia Market, By Region, From 2020 to 2025 (USD Million)
  12. Europe Meningitis Market, By Region, From 2020 to 2025 (USD Million)
  13. Europe Sinusitis Market, By Region, From 2020 to 2025 (USD Million)
  14. Europe Otitis Market, By Region, From 2020 to 2025 (USD Million)
  15. Europe Pneumonia Market, By Region, From 2020 to 2025 (USD Million)
  16. Europe CNS Market, By Region, From 2020 to 2025 (USD Million)
  17. Europe Urinary Market, By Region, From 2020 to 2025 (USD Million)
  18. Europe Respiratory Infections Market, By Region, From 2020 to 2025 (USD Million)
  19. Europe Neisseriaceae Infections Market, By Antibacterial Drugs, From 2020 to 2025 (USD Million)
  20. Europe B-lactum Antibiotics (Penicillin) Market, By Region, From 2020 to 2025 (USD Million)
  21. Europe Clavulanic Acid (Augmentin) Market, By Region, From 2020 to 2025 (USD Million)
  22. Europe Aminoglycosides (Streptomycin) Market, By Region, From 2020 to 2025 (USD Million)
  23. Europe Glycopeptides (Vancomycin) Market, By Region, From 2020 to 2025 (USD Million)
  24. Europe Polypeptides (Bacitracin) Market, By Region, From 2020 to 2025 (USD Million)
  25. Europe Rifamycins (Rifampicin) Market, By Region, From 2020 to 2025 (USD Million)
  26. Europe chloramphenicol, Market, By Region, From 2020 to 2025 (USD Million)
  27. Europe tetracycline Market, By Region, From 2020 to 2025 (USD Million)
  28. Europe Others Market, By Region, From 2020 to 2025 (USD Million)
  29. U.K. Neisseriaceae Infections Market, By Type Of Bacteria, From 2020 to 2025 (USD Million)
  30. U.K. Neisseriaceae Infections Market, By Disease, From 2020 to 2025 (USD Million)
  31. U.K. Neisseriaceae Infections Market, By Antibacterial Drugs, From 2020 to 2025 (USD Million)
  32. Germany Neisseriaceae Infections Market, By Type Of Bacteria, From 2020 to 2025 (USD Million)
  33. Germany Neisseriaceae Infections Market, By Disease, From 2020 to 2025 (USD Million)
  34. Germany Neisseriaceae Infections Market, By Antibacterial Drugs, From 2020 to 2025 (USD Million)
  35. France Neisseriaceae Infections Market, By Type Of Bacteria, From 2020 to 2025 (USD Million)
  36. France Neisseriaceae Infections Market, By Disease, From 2020 to 2025 (USD Million)
  37. France Neisseriaceae Infections Market, By Antibacterial Drugs, From 2020 to 2025 (USD Million)
  38. Italy Neisseriaceae Infections Market, By Type Of Bacteria, From 2020 to 2025 (USD Million)
  39. Italy Neisseriaceae Infections Market, By Disease, From 2020 to 2025 (USD Million)
  40. Italy Neisseriaceae Infections Market, By Antibacterial Drugs, From 2020 to 2025 (USD Million)
  41. Spain Neisseriaceae Infections Market, By Type Of Bacteria, From 2020 to 2025 (USD Million)
  42. Spain Neisseriaceae Infections Market, By Disease, From 2020 to 2025 (USD Million)
  43. Spain Neisseriaceae Infections Market, By Antibacterial Drugs, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample